Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
What is the purpose of this trial?
The purpose of this study is to compare the efficacy and safety of maribavir to valganciclovir for the treatment of cytomegalovirus (CMV) infection in asymptomatic hematopoietic stem cell transplant recipients.
- Ages16 years and older
- Trial withShire ViroPharma, Inc.
- Start Date06/01/2018
- End Date08/01/2019
- Last Updated07/15/2021
- Study HIC#2000021433